van der Zijden, Charlène J.
Lagarde, Sjoerd M.
Mostert, Bianca
Nuyttens, Joost J. M. E.
Spaander, Manon C. W.
Wijnhoven, Bas P. L.
van Sandick, Johanna W.
van Dieren, Jolanda M.
Voncken, Francine E. M.
Pierie, Jean-Pierre E. N.
Fiets, Willem E.
Rosman, Camiel
Siersema, Peter D.
Rütten, Heidi
Nieuwenhuijzen, Grard A. P.
Creemers, Geert-Jan
Schoon, Erik J.
van der Sangen, Maurice J. C.
Verschoor, Arjan
Quisel, Rutger
Sosef, Meindert N.
Buijsen, Jeroen
Hartgrink, Hendrik H.
Slingerland, Marije
Heisterkamp, Joos
Beerepoot, Laurens V.
Hazen, Wouter L.
Rozema, Tom
Muller, Karin
Kouwenhoven, Ewout A.
Law, Simon Y.
Chan, Wendy W.
Wong, Ian Y.
Li, Zhigang
Chao, Yin-Kai
Wu, I-Chen
Wu, Chiao-En
Yap, Wing-Keen
Park, Seong Yong
Takeuchi, Hiroya
Booka, Eisuke
Kato, Ken
Yoshinori, Ito
Lin, Steven H.
Piessen, Guillaume
Turpin, Anthony
Taillez, Alexandre
Castoro, Carlo
Bastoni, Alessandro
Maselli, Roberta
Scorsetti, Marta
Walsh, Thomas N.
Grogan, Liam
,
,
Article History
First Online: 29 June 2024
Disclosures
: Bianca Mostert: research funding from Sanofi, Pfizer and BMS; consulting/advisory for Lilly, Servier, BMS, Amgen and AstraZeneca. Bas Wijnhoven: research funding from BMS; consulting/advisory for BMS. Grard Nieuwenhuijzen: Consulting/advisory for Medtronic, Lilly. Guillaume Piessen: consulting/advisory for Nestle, BMS, MSD, Daiichi, Astellas. Ewout A. Kouwenhoven: consulting/advisory for Intuitive Surgical. Ken Kato: research funding from ONO, BMS, MSD; consulting/advisory for BMS, MSD, Beigene, Chugai, and BAYER. All remaining authors have declared no conflicts of interest.